Nothing Special   »   [go: up one dir, main page]

TR200101765T2 - Prostaglandin endoperoksit H sentaz biyosentez inhibitörleri - Google Patents

Prostaglandin endoperoksit H sentaz biyosentez inhibitörleri

Info

Publication number
TR200101765T2
TR200101765T2 TR2001/01765T TR200101765T TR200101765T2 TR 200101765 T2 TR200101765 T2 TR 200101765T2 TR 2001/01765 T TR2001/01765 T TR 2001/01765T TR 200101765 T TR200101765 T TR 200101765T TR 200101765 T2 TR200101765 T2 TR 200101765T2
Authority
TR
Turkey
Prior art keywords
cox
inhibitors
biosynthesis inhibitors
prostaglandin endoperoxide
cyclooxygenase
Prior art date
Application number
TR2001/01765T
Other languages
English (en)
Inventor
A. Black Lawrence
Basha Anwer
Kolasa Teodozyj
E. Kort Michael
Liu Huaqing
M. Mccarty Catherine
V. Patel Meena
J. Rohde Jeffrey
J. Coghlan Michael
O. Stewart Andrew
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority claimed from US09/427,768 external-priority patent/US6307047B1/en
Publication of TR200101765T2 publication Critical patent/TR200101765T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Bu bulus siklooksijenaz (COX) inhibitörleri olan ve özellikle seçici siklooksijenaz-2 (COX-2) inhibitörleri olan formül (I) bilesiklerini açiklamaktadir. COX-2 mide-bagirsak sistemi ve böbrekler de dahil olmak üzere birçok dokuda önemli bir "kahya" enzim olan olusturucu izoform siklooksijenaz-1'in (COX-1) tersine enflamasyonla iliskili indüklenebilir izoformdur. Bu bilesiklerin COX-2 için seçiciligi günümüzde piyasada bulunan steroidal olmayan anti enflamatuar ilaçlarda (NSAID'ler) görülen istenmeyen mide-bagirsak ve böbrek yan etkilerini en aza indirmektedir.
TR2001/01765T 1998-10-27 1999-10-27 Prostaglandin endoperoksit H sentaz biyosentez inhibitörleri TR200101765T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17960598A 1998-10-27 1998-10-27
US26187299A 1999-03-03 1999-03-03
US29849099A 1999-04-23 1999-04-23
US09/427,768 US6307047B1 (en) 1997-08-22 1999-10-27 Prostaglandin endoperoxide H synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
TR200101765T2 true TR200101765T2 (tr) 2002-02-21

Family

ID=27497355

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01765T TR200101765T2 (tr) 1998-10-27 1999-10-27 Prostaglandin endoperoksit H sentaz biyosentez inhibitörleri

Country Status (19)

Country Link
EP (1) EP1124804B1 (tr)
JP (1) JP2003512292A (tr)
KR (1) KR100666838B1 (tr)
CN (1) CN1279026C (tr)
AT (1) ATE302759T1 (tr)
BG (1) BG65261B1 (tr)
BR (1) BR9914858A (tr)
CA (1) CA2347982A1 (tr)
CZ (1) CZ300570B6 (tr)
DE (1) DE69926903T2 (tr)
DK (1) DK1124804T3 (tr)
ES (1) ES2249919T3 (tr)
HK (1) HK1041876B (tr)
HU (1) HUP0105248A3 (tr)
NO (1) NO318623B1 (tr)
PL (1) PL198503B1 (tr)
SK (1) SK286806B6 (tr)
TR (1) TR200101765T2 (tr)
WO (1) WO2000024719A1 (tr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100626605B1 (ko) 1997-11-19 2006-09-22 코와 가부시키가이샤 신규 피리다진 유도체 및 이를 유효성분으로 하는 의약
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
TWI290130B (en) 2000-09-15 2007-11-21 Pharmacia Corp 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
DK1490064T3 (da) 2002-02-14 2010-01-04 Pharmacia Corp Substituerede pyridinoner som modulatorer af p38 MAP kinase
PL377657A1 (pl) 2002-12-13 2006-02-06 Warner-Lambert Company Llc Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7211577B2 (en) 2003-03-18 2007-05-01 Kowa Co., Ltd. Water-soluble phenylpyridazine derivative and medicine containing the same
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1916240A1 (en) * 2006-10-25 2008-04-30 Syngeta Participations AG Pyridazine derivatives
CA2673545A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
DE102007008843A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen
DE102007008840A1 (de) * 2007-02-23 2008-08-28 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007008839A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen
DE102007020690A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007020689A1 (de) 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP)
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
GB0716414D0 (en) * 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
CN101809021B (zh) 2007-09-11 2013-04-24 雅培制药有限公司 八氢-吡咯并[3,4-b]吡咯n-氧化物
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
FR2969606B1 (fr) * 2010-12-22 2013-01-11 Pf Medicament Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
WO2021124344A1 (en) * 2019-12-18 2021-06-24 Abida Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238490A (en) * 1979-02-12 1980-12-09 Diamond Shamrock Corporation Antihypertensive pyridazin(2H)-3-ones
JPS57501328A (tr) * 1980-08-07 1982-07-29
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
EP0833664A1 (en) * 1995-06-12 1998-04-08 G.D. SEARLE & CO. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b 4? receptor antagonist for the treatment of inflammations
DE69825154T2 (de) * 1997-03-14 2005-07-21 Merck Frosst Canada & Co, Kirkland Pyridazinone als inhibitoren von cyclooxygenase-2
WO1999010332A1 (en) * 1997-08-22 1999-03-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
WO1999010331A1 (en) * 1997-08-22 1999-03-04 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
KR100675028B1 (ko) * 1997-08-22 2007-01-29 아보트 러보러터리즈 프로스타글란딘 엔도퍼옥사이드 ｈ 신타제 생합성 억제제로서의 아릴피리다지논, 이를 포함하는 약제학적 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
EP1124804A1 (en) 2001-08-22
EP1124804B1 (en) 2005-08-24
PL198503B1 (pl) 2008-06-30
KR100666838B1 (ko) 2007-01-11
PL349256A1 (en) 2002-07-01
DE69926903D1 (en) 2005-09-29
HK1041876B (zh) 2006-06-23
HK1041876A1 (en) 2002-07-26
CN1279026C (zh) 2006-10-11
ATE302759T1 (de) 2005-09-15
WO2000024719A1 (en) 2000-05-04
JP2003512292A (ja) 2003-04-02
BG105523A (en) 2001-12-29
CN1342149A (zh) 2002-03-27
CZ20011481A3 (cs) 2001-09-12
DE69926903T2 (de) 2006-07-13
BG65261B1 (bg) 2007-10-31
NO20012061L (no) 2001-06-27
CZ300570B6 (cs) 2009-06-17
SK286806B6 (sk) 2009-05-07
DK1124804T3 (da) 2005-12-12
ES2249919T3 (es) 2006-04-01
KR20010081101A (ko) 2001-08-27
NO20012061D0 (no) 2001-04-26
SK5542001A3 (en) 2001-12-03
NO318623B1 (no) 2005-04-18
BR9914858A (pt) 2002-02-05
HUP0105248A2 (hu) 2002-07-29
CA2347982A1 (en) 2000-05-04
HUP0105248A3 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
TR200101765T2 (tr) Prostaglandin endoperoksit H sentaz biyosentez inhibitörleri
CA2299300A1 (en) Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
CY1105027T1 (el) Αναστολεις της βιοσυνθεσης της συνθασης του ενδοϋπεροξειδιου η της προσταγλανδινης
Botting Inhibitors of cyclooxygenases: mechanisms, selectivity and uses
Zhou et al. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase
Riendeau et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2
Liu et al. Involvement of cyclo‐oxygenase‐1‐mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries
Koeberle et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1
Spiegelman et al. A small‐molecule SIRT2 inhibitor that promotes K‐Ras4a lysine fatty‐acylation
Cascella et al. Kinetic analysis of iron-dependent histone demethylases: α-ketoglutarate substrate inhibition and potential relevance to the regulation of histone demethylation in cancer cells
ATE514703T1 (de) Hydrolyseresistente organomodifizierte disiloxantenside
Dadashpour et al. Design, synthesis and in vitro study of 5, 6‐diaryl‐1, 2, 4‐triazine‐3‐ylthioacetate derivatives as COX‐2 and β‐amyloid aggregation inhibitors
Liu et al. Concomitant activation of functionally opposing prostacyclin and thromboxane prostanoid receptors by cyclo‐oxygenase‐1‐mediated prostacyclin synthesis in mouse arteries
Zhou et al. Cyclo‐oxygenase‐1 or‐2‐mediated metabolism of arachidonic acid in endothelium‐dependent contraction of mouse arteries
TR200000478T2 (tr) Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar.
ATE443775T1 (de) Hif-prolylhydroxylase-aktivitätstest
GB2395996A (en) Flexible coupling with radially offset beams formed by asymmetric slot pairs
More et al. Effect of S-methylisothiourea in acetaminophen-induced hepatotoxicity in rat
Rowland et al. Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic,[3-(3, 4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2-(5H)-furanone], in multiple preclinical species
Curnock et al. Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and-2: comparison with nonsteroidal anti-inflammatory drugs
DE69931814D1 (de) Umwandlung von cox-inhibierenden, nicht cox-2 selektiven inhibitoren in derivate von cox-2 selektiven inhibitoren
Izzo et al. Cyclooxygenase in GtoPdb v. 2023.1
Zhao et al. Structure of the Sir2 family of NAD+-dependent histone/protein deacetylases
Heimbucher et al. Investigating Mechanisms that Control Ubiquitin-Mediated DAF-16/FOXO Protein Turnover
Dallob et al. Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration